Baseline characteristics
| Characteristic . | All patients . | Fracture . | No fracture . | |
|---|---|---|---|---|
| (N = 729)* . | (n = 81)* . | (n = 648)* . | ||
| Age, median (range), y | 76.8 (69.5-96.4) | 76.7 (69.5-96.4) | 77.2 (9.5-90.5) | |
| Sex, n (%) | ||||
| Male | 353 (48.4) | 29 (35.8) | 324 (50.0) | |
| Female | 376 (51.6) | 52 (64.2) | 324 (50.0) | |
| ECOG performance score, n (%) | ||||
| 0-1 | 491 (68.0) | 56 (71.8) | 435 (67.5) | |
| 2-4 | 231 (32.0) | 22 (28.2) | 209 (32.5) | |
| IPI score grouped, n (%) | ||||
| IPI 1-2 | 328 (46.4) | 34 (43.0) | 294 (46.8) | |
| IPI 3-5 | 379 (53.6) | 45 (57.0) | 334 (53.2) | |
| BMI group, n (%) | ||||
| Underweight | 32 (4.4) | 5 (6.2) | 27 (4.2) | |
| Normal | 317 (43.8) | 32 (39.5) | 285 (44.4) | |
| Overweight | 237 (32.8) | 25 (30.9) | 212 (33.0) | |
| Obese | 137 (18.9) | 19 (23.5) | 118 (18.4) | |
| Relevant comorbidities and predisposing history, n (%) | ||||
| Current smoker | ||||
| No | 617 (95.1) | 72 (94.7) | 545 (95.1) | |
| Yes | 32 (4.9) | 4 (5.3) | 28 (4.9) | |
| Known osteoporosis | ||||
| No | 680 (94.3) | 71 (87.7) | 609 (95.2) | |
| Yes | 41 (5.7) | 10 (12.3) | 31 (4.8) | |
| Known osteopenia | ||||
| No | 689 (96.1) | 74 (91.4) | 615 (96.7) | |
| Yes | 28 (3.9) | 7 (8.6) | 21 (3.3) | |
| Family history of osteoporosis | ||||
| No | 329 (99.1) | 29 (93.5) | 300 (99.7) | |
| Yes | 3 (0.9) | 2 (6.5) | 1 (0.3) | |
| RA | ||||
| No | 690 (95.8) | 74 (91.4) | 616 (96.4) | |
| Yes | 30 (4.2) | 7 (8.6) | 23 (3.6) | |
| Type 2 diabetes | ||||
| No | 635 (88.3) | 70 (86.4) | 565 (88.6) | |
| Yes | 84 (11.7) | 11 (13.6) | 73 (11.4) | |
| Inflammatory bowel disease | ||||
| No | 707 (98.6) | 81 (100.0) | 626 (98.4) | |
| Yes | 10 (1.4) | 0 (0.0) | 10 (1.6) | |
| History of excess alcohol use | ||||
| No | 614 (95.5) | 76 (98.7) | 538 (95.1) | |
| Yes | 29 (4.5) | 1 (1.3) | 28 (4.9) | |
| Prior steroids in last 12 mo | ||||
| No | 614 (95.5) | 76 (98.7) | 538 (95.1) | |
| Yes | 29 (4.5) | 1 (1.3) | 28 (4.9) | |
| Bone-protective medication (any)† | ||||
| No medication, no predisposing history‡ | 534 (75.9) | 48 (62.3) | 486 (77.5) | |
| No medication, predisposing history | 69 (9.8) | 12 (15.6) | 57 (9.1) | |
| Medication, no predisposing history | 48 (6.8) | 4 (5.2) | 44 (7.0) | |
| Medication and predisposing history | 53 (7.5) | 13 (16.9) | 40 (6.4) | |
| Fracture history and bone involvement, n (%) | ||||
| Prior fracture | ||||
| No | 617 (85.3) | 62 (76.5) | 555 (86.4) | |
| Yes | 44 (6.1) | 4 (4.9) | 40 (6.2) | |
| Fracture at baseline | 62 (8.6) | 15 (18.5) | 47 (7.3) | |
| Non-lymphoma–related fracture at diagnosis | ||||
| No | 705 (97.2) | 77 (95.1) | 628 (97.5) | |
| Yes | 20 (2.8) | 4 (4.9) | 16 (2.5) | |
| Baseline fracture due to DLBCL | ||||
| No | 678 (93.5) | 68 (85.0) | 610 (94.6) | |
| Yes | 47 (6.5) | 12 (15.0) | 35 (5.4) | |
| Bone involvement | ||||
| None | 559 (76.7) | 46 (56.8) | 513 (79.2) | |
| Involvement, no fracture | 123 (16.9) | 23 (28.4) | 100 (15.4) | |
| Involvement, fracture | 47 (6.4) | 12 (14.8) | 35 (5.4) | |
| Biochemical parameters, n (%) | ||||
| ALP level, high | ||||
| No | 593 (82.8) | 65 (81.3) | 528 (83.0) | |
| Yes | 123 (17.2) | 15 (18.8) | 108 (17.0) | |
| Calcium level | ||||
| Low | 9 (1.3) | 1 (1.3) | 8 (1.3) | |
| Normal | 600 (87.1) | 69 (88.5) | 531 (86.9) | |
| High | 80 (11.6) | 8 (10.3) | 72 (11.8) | |
| Characteristic . | All patients . | Fracture . | No fracture . | |
|---|---|---|---|---|
| (N = 729)* . | (n = 81)* . | (n = 648)* . | ||
| Age, median (range), y | 76.8 (69.5-96.4) | 76.7 (69.5-96.4) | 77.2 (9.5-90.5) | |
| Sex, n (%) | ||||
| Male | 353 (48.4) | 29 (35.8) | 324 (50.0) | |
| Female | 376 (51.6) | 52 (64.2) | 324 (50.0) | |
| ECOG performance score, n (%) | ||||
| 0-1 | 491 (68.0) | 56 (71.8) | 435 (67.5) | |
| 2-4 | 231 (32.0) | 22 (28.2) | 209 (32.5) | |
| IPI score grouped, n (%) | ||||
| IPI 1-2 | 328 (46.4) | 34 (43.0) | 294 (46.8) | |
| IPI 3-5 | 379 (53.6) | 45 (57.0) | 334 (53.2) | |
| BMI group, n (%) | ||||
| Underweight | 32 (4.4) | 5 (6.2) | 27 (4.2) | |
| Normal | 317 (43.8) | 32 (39.5) | 285 (44.4) | |
| Overweight | 237 (32.8) | 25 (30.9) | 212 (33.0) | |
| Obese | 137 (18.9) | 19 (23.5) | 118 (18.4) | |
| Relevant comorbidities and predisposing history, n (%) | ||||
| Current smoker | ||||
| No | 617 (95.1) | 72 (94.7) | 545 (95.1) | |
| Yes | 32 (4.9) | 4 (5.3) | 28 (4.9) | |
| Known osteoporosis | ||||
| No | 680 (94.3) | 71 (87.7) | 609 (95.2) | |
| Yes | 41 (5.7) | 10 (12.3) | 31 (4.8) | |
| Known osteopenia | ||||
| No | 689 (96.1) | 74 (91.4) | 615 (96.7) | |
| Yes | 28 (3.9) | 7 (8.6) | 21 (3.3) | |
| Family history of osteoporosis | ||||
| No | 329 (99.1) | 29 (93.5) | 300 (99.7) | |
| Yes | 3 (0.9) | 2 (6.5) | 1 (0.3) | |
| RA | ||||
| No | 690 (95.8) | 74 (91.4) | 616 (96.4) | |
| Yes | 30 (4.2) | 7 (8.6) | 23 (3.6) | |
| Type 2 diabetes | ||||
| No | 635 (88.3) | 70 (86.4) | 565 (88.6) | |
| Yes | 84 (11.7) | 11 (13.6) | 73 (11.4) | |
| Inflammatory bowel disease | ||||
| No | 707 (98.6) | 81 (100.0) | 626 (98.4) | |
| Yes | 10 (1.4) | 0 (0.0) | 10 (1.6) | |
| History of excess alcohol use | ||||
| No | 614 (95.5) | 76 (98.7) | 538 (95.1) | |
| Yes | 29 (4.5) | 1 (1.3) | 28 (4.9) | |
| Prior steroids in last 12 mo | ||||
| No | 614 (95.5) | 76 (98.7) | 538 (95.1) | |
| Yes | 29 (4.5) | 1 (1.3) | 28 (4.9) | |
| Bone-protective medication (any)† | ||||
| No medication, no predisposing history‡ | 534 (75.9) | 48 (62.3) | 486 (77.5) | |
| No medication, predisposing history | 69 (9.8) | 12 (15.6) | 57 (9.1) | |
| Medication, no predisposing history | 48 (6.8) | 4 (5.2) | 44 (7.0) | |
| Medication and predisposing history | 53 (7.5) | 13 (16.9) | 40 (6.4) | |
| Fracture history and bone involvement, n (%) | ||||
| Prior fracture | ||||
| No | 617 (85.3) | 62 (76.5) | 555 (86.4) | |
| Yes | 44 (6.1) | 4 (4.9) | 40 (6.2) | |
| Fracture at baseline | 62 (8.6) | 15 (18.5) | 47 (7.3) | |
| Non-lymphoma–related fracture at diagnosis | ||||
| No | 705 (97.2) | 77 (95.1) | 628 (97.5) | |
| Yes | 20 (2.8) | 4 (4.9) | 16 (2.5) | |
| Baseline fracture due to DLBCL | ||||
| No | 678 (93.5) | 68 (85.0) | 610 (94.6) | |
| Yes | 47 (6.5) | 12 (15.0) | 35 (5.4) | |
| Bone involvement | ||||
| None | 559 (76.7) | 46 (56.8) | 513 (79.2) | |
| Involvement, no fracture | 123 (16.9) | 23 (28.4) | 100 (15.4) | |
| Involvement, fracture | 47 (6.4) | 12 (14.8) | 35 (5.4) | |
| Biochemical parameters, n (%) | ||||
| ALP level, high | ||||
| No | 593 (82.8) | 65 (81.3) | 528 (83.0) | |
| Yes | 123 (17.2) | 15 (18.8) | 108 (17.0) | |
| Calcium level | ||||
| Low | 9 (1.3) | 1 (1.3) | 8 (1.3) | |
| Normal | 600 (87.1) | 69 (88.5) | 531 (86.9) | |
| High | 80 (11.6) | 8 (10.3) | 72 (11.8) | |
ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index.
Missing data were excluded from denominators.
Bone-protective medication includes vitamin D, calcium, and/or bisphosphonates.
Predisposing history defined by known osteoporosis, osteopenia, RA, or prior fracture.